Glori Energy, the sustainable oil recovery system developer, has taken a $20 million Series C round that was led by Gentry Venture Partners. Advantage Capital Partners joined Energy Technology Ventures (a GE, NRG Energy and ConocoPhillips joint venture), GTI Ventures, Kleiner Perkins Caufield & Byers (KPCB), Oxford Bioscience Partners, Malaysian Life Sciences Capital Fund, and The Omzest Group on the transaction and Piper Jaffray served as placement agent.

Rib-X Pharmaceuticals Inc., a New Haven, Conn.-based pharmaceutical developer, has filed plans for an initial public offering to raise up to $80 million. The company had previously raised capital from investors including Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, MedImmune Ventures, Oxford Bioscience Partners and S.R. One. Deutsche Bank Securities will act as the sole book-running manager for the offering. William Blair & Company, Lazard Capital Markets and Needham & Co. will act as co-managers.

In peHUB’s continuing series of slideshows on venture funds and fund performance, we’ve looked at funds through the lens of IRRs, annual commitment trends and cash returns. Here is another look at cash returns that is more troubling than becoming. We isolated the 39 venture capital funds in the University of California’s private equity portfolio [...]

Secondary direct investment firm Saints Capital is teaming up with Oxford Bioscience Partners and making an investment in a partnership with Oxford that will make follow on investments in six positions initially owned by Oxford. In conjunction with the transaction, Terry Vance, formerly a Managing Director at EGS Healthcare Capital Partners, is joining Saints as a venture partner to manage certain positions in the new partnership.

Private equity firm Symphony Technology Partners has acquired a majority stake in ImpactRx, a developer of a subscription database for pharmaceutical companies. The company, based in Mr. Laurel, N.J., had recently closed a $1.2 million Series E round in January, and was backed by roughly $36 million from investors including Mediphase Venture Partners, 3i Group, Oxford Bioscience Partners and Merck Capital Ventures. Financial terms of the acquisition by Symphony Technology Group were not released.

Guilford, Conn.-based online advertising start-up uKnow has raised roughly half of a planned $1 million funding round, according to a filing with the SEC. Angel investor Geoff Judge, who is also a partner with iNovia Capital, is listed among the company’s directors. Pittsburgh-based Neograft has raised $3 million according to an SEC filing. Neograft develops [...]

Doug Fambrough has stepped down as a general partner with Oxford Bioscience Partners, in order to become CEO of Oxford portfolio company Dicerna Pharmaceuticals Inc. He will remain as a venture partner with Oxford. Dicerna is a Cambridge, Mass.-based RNA interference company that has raised $21.4 million in VC funding from Oxford, Abingworth Management and Skyline Ventures.

He tells peHUB that Dicerna will likely seek between $25 million and $30 million in new VC funding during the second half of this year.

Seahorse Bioscience, Inc., a Billerica, Mass.-based medical instrument company, closed a $5 million round of financing. Investors in the Series D round included Commonwealth Capital Ventures, FLIR Systems Inc, Rock Maple Ventures, Life Sciences Partners, Oxford Bioscience Partners, Healthcare Ventures, New Science Ventures and HLM Venture Partners.

Jeffrey Barnes this morning was asked to resign as a general partner with Oxford Bioscience Partners, after the firm learned that he had not complied with policies governing personal securities trading. An OBP spokesman says that he did so with immediate effect, and that it is not expected to have a “material effect” on portfolio performance or firm operations.

The spokesman adds that Barnes’ transgression involved personally trading in publicly-held OBP portfolio companies without the knowledge of his fellow partners.

Barnes originally joined the Boston-based venture capital firm in 1999, after having spent time in the healthcare M&A trenches with both Robbie Stephens and Needham & Co. Before that, he was co-founder and CEO of cardiovascular device company Biosyss Corp. He was one of five general partners on the firm’s $150 million fifth fund, which closed

Pathway Medical Technologies, a developer of endovascular treatments for peripheral arterial disease received a $1.5 million investment from Washington Research Foundation, independent, nonprofit foundation, as part of the company’s Series D financing. The round totals $42.5 million with investments from Forbion Capital Partners, Giza Venture Capital, HLM Venture Partners, Latterell Venture Partners, and Oxford Bioscience [...]